This article was originally published here<\/p>\n
J Am Acad Dermatol. 2021 Jan 7:S0190-9622(21)00016-5. doi: 10.1016\/j.jaad.2020.12.058. Online ahead of print.<\/p>\n
ABSTRACT<\/p>\n
OBJECTIVE: To update guidance regarding the management of psoriatic disease during the COVID-19 pandemic.<\/p>\n
STUDY DESIGN: The task force (TF) includes 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care. The TF was supplemented by non-voting members, which included fellows and National Psoriasis Foundation (NPF) staff. Clinical questions relevant to the psoriatic disease community were informed by inquiries received by the NPF. A Delphi process was conducted.<\/p>\n
RESULTS: The TF updated evidence for the original 22 statements and added 5 new recommendations. The average of the votes was within the category of agreement for all statements, 13 with high consensus, 14 with moderate consensus.<\/p>\n
LIMITATIONS: The evidence behind many guidance statements is variable in quality and\/or quantity.<\/p>\n
CONCLUSION: These statements provide guidance for the management of patients with psoriatic disease on topics ranging from how the disease and its treatments impact COVID-19 risk, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with SARS-CoV-2 (including novel vaccination), and what they should do if they develop COVID-19. The guidance is a living document that is continuously updated by the TF as data emerge.<\/p>\n
PMID:33422626 | DOI:10.1016\/j.jaad.2020.12.058<\/p>\n
<\/p>\n
Read the original post: This article was originally published here J Am Acad Dermatol. 2021 Jan 7:S0190-9622(21)00016-5 Continue reading
\nNational Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 2 - Advances in Psoriatic...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"